Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903837 · ClinicalTrials.gov registry record · Phase 2
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 2
- Development phase
- 347
- Enrollment target
NCT01903837 is a Phase 2 study that has completed, run by Alkermes. The registered enrollment target is 347 participants.
The verdict
NCT01903837, a Phase 2 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 347 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, placebo-controlled multicenter study, which will be conducted in 2 parts. The study duration for each subject will be approximately 33 weeks and will include 25 study visits.
Interventions
- DRUG Placebo
- DRUG Olanzapine
- DRUG Samidorphan (Low Dose)
- DRUG Samidorphan (Medium Dose)
- DRUG Samidorphan (High Dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01903837
The ClinicalTrials.gov registry entry for NCT01903837 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01903837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01903837 about?
NCT01903837 is a clinical study titled "A Study of ALKS 3831 in Adults With Schizophrenia". This is a Phase 2, randomized, placebo-controlled multicenter study, which will be conducted in 2 parts. The study duration for each subject will be approximately 33 weeks and will include 25 study visits.
What is the current status of trial NCT01903837?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 347 participants. The study started on 2013-06. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01903837?
The interventions under investigation include: Placebo (DRUG), Olanzapine (DRUG), Samidorphan (Low Dose) (DRUG), Samidorphan (Medium Dose) (DRUG), Samidorphan (High Dose) (DRUG).
Who is sponsoring clinical trial NCT01903837?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.